Ovarian Cancer

New phase 2 data confirms the Avmapki Fakzynja Co-pack offers lasting efficacy and stable safety for patients with recurrent KRAS-mutated LGSOC.

Phase 3 ROSELLA data shows relacorilant and nab-paclitaxel reduced death risk by 35% in platinum-resistant ovarian cancer, a new preferred treatment.

The FDA has granted Fast Track designation to the FRα-targeting ADC ZW191 as a potential treatment for patients with for platinum-resistant ovarian cancer.

The FDA approved the combination of relacorilant and nab-paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

The FDA approved IV and subcutaneous pembrolizumab with paclitaxel with or without bevacizumab for patients with platinum-resistant ovarian cancers.

Updates in ovarian cancer include multiple fast track designations and breakthrough therapy status for new drugs in the clinical space.

The FDA granted JSKN003 breakthrough therapy status for gynecologic cancers based on data from the phase 1 JSKN003-101 and phase 1/2 JSKN003-102 trials.

Hormone replacement therapy was associated with a lower risk of developing BRCA1- or BRCA2-mutated breast cancer among those already at higher risk.

Pembrolizumab plus paclitaxel with or without bevacizumab boosted survival in patients with platinum-resistant, recurrent ovarian cancer.

Integrating PRO tools in survivorship care may help oncology nurses address ongoing emotional and physical needs of ovarian cancer survivors.

Relacorilant’s new drug application for platinum-resistant ovarian cancer has been accepted by the FDA.

Understanding which patients may benefit from CLDN6-targeting immunotherapy and recognizing potential adverse effects is essential for oncology nurses.

The addition of avutometinib to defactinib showed promising safety and efficacy for patients with low-grade serous ovarian cancer.

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

The FDA approved the first oral treatments for paraganglioma, pheochromocytoma, and anal cancer in May.

KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.

The FDA has granted accelerated approval to avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis of the phase 3 ARTISTRY-7 trial.

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.